Zacks Reiterates Neutral on Accuray Incorporated (ARAY)

By admin | 6 years ago

Accuray Incorporated (NASDAQ: ARAY)‘s stock had its “neutral” rating reiterated by Zacks in a research note issued to investors on Wednesday. They currently have a $6.50 price target on the stock.

ARAY has been the subject of a number of other recent research reports. Analysts at Dougherty & Co initiated coverage on shares of Accuray Incorporated in a research note to investors on Wednesday, April 18th. They set a “buy” rating and a $9.50 price target on the stock. Separately, analysts at B. Riley initiated coverage on shares of Accuray Incorporated in a research note to investors on Wednesday, April 4th. They set a “buy” rating on the stock. Finally, analysts at Sidoti initiated coverage on shares of Accuray Incorporated in a research note to investors on Wednesday, March 14th. They set a “buy” rating on the stock.

Accuray Incorporated opened at 6.01 on Wednesday. Accuray Incorporated has a 52-week low of $3.50 and a 52-week high of $9.07. The company’s market cap is $428.5 million.

Accuray Incorporated last posted its quarterly earnings results on Tuesday, May 8th. The company reported ($0.21) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.14) by $0.07. Accuray Incorporated’s revenue was up 86.0% compared to the same quarter last year. Analysts expect that Accuray Incorporated will post $-0.11 EPS next quarter.

Accuray Incorporated has developed a robotic radiosurgery system, CyberKnife Robotic Radiosurgery System, designed to treat solid tumors anywhere in the body as an alternative to traditional surgery.

About the author